Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: A nonrandomized study in healthy volunteers

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 2, 2006, Pages 117-126

  Leach, Chet L ^a   Bethke, Thomas D ^b   Boudreau, Robert J ^c   Hasselquist, Bruce E ^c   Drollmann, Anton ^b   Davidson, Patricia ^d   Wurst, Wilhelm ^b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b ALTANA PHARMA AG   (Germany)

^c UNIVERSITY OF MINNESOTA   (United States)

^d 3M COMPANY   (United States)

Author keywords

Asthma; Ciclesonide; Lung deposition; Metered dose inhaler

Indexed keywords

CICLESONIDE; FLUORINATED HYDROCARBON; NORFLURANE; PROPELLANT; TECHNETIUM 99M;

ABSENCE OF SIDE EFFECTS; ADULT; AEROSOL; APPARATUS; ARTICLE; ASTHMA; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG LUNG DEPOSITION; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGING SYSTEM; MALE; METERED DOSE INHALER; MOUTH; NORMAL HUMAN; OPEN STUDY; OROPHARYNX; PHARYNX; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TWO DIMENSIONAL IMAGING;

ADMINISTRATION, INHALATION; ADULT; AEROSOL PROPELLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCARBONS, FLUORINATED; IMAGING, THREE-DIMENSIONAL; LUNG; MALE; METERED DOSE INHALERS; MIDDLE AGED; OROPHARYNX; PREGNENEDIONES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33745601984     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.117     Document Type: Article

References (45)

1. Dietzel, K., R. Engelstätter, and A. Keller 2001. Ciclesonide: an on-site-activated steroid. In T.T. Hansel and P.J. Barnes, eds. New Drugs for Asthma, Allergy and COPD. Progress in Respiratory Research, Vol. 31. Ss. Karger, Basel, Switzerland. 91-93.
2. Eigen, H., B.J. Rosenstein, S. FitzSimmons, et al. 1995. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J. Pediatr. 126:515-523.
3. Allen, D.B. 1996. Growth suppression by glucocorticoid therapy. Endocrinol. Metab. Clin. North Am. 25:699-717.
4. Allen, D.B. 1998. Influence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective. Acta Paediatr. 87:123-129.
5. Doull, I.J., N.J. Freezer, and S.T. Holgate. 1995. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am. J. Respir. Crit. Care Med. 151:1715-1719.
6. Allen, D.B., M. Mullen, and B. Mullen. 1994. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J. Allergy Clin. Immunol. 93:967-976.
7. Todd, G., K. Durdop, J. McNaboe, et al. 1996. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 348:27-29.
8. Lai, H.C., S.C. FitzSimmons, D.B. Allen, et al. 2000. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N. Engl. J. Med. 342:851-859.
9. Clark, D.J., A. Grove, R.I. Cargill, et al. 1996. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 51:262-266.
10. Grahnen, A., B. Jansson, R.M. Brundin, et al. 1997. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur. J. Clin. Pharmacol. 52:261-267.
11. Thorsson, L., K. Dahlstrom, S. Edsbacker, et al. 1997. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br. J. Clin. Pharmacol. 43:155-161.
12. Cumming, R.G., P. Mitchell, and S.R. Leeder. 1997. Use of inhaled corticosteroids and the risk of cataracts. N. Engl. J. Med. 337:8-14.
13. Jackson, L.D., D. Polygenis, R.A. McIvor, et al. 1999. Comparative efficacy and safety of inhaled corticosteroids in asthma. Can. J. Clin. Pharmacol. 6:26-37.
14. Dent, G. 2002. Ciclesonide (Byk Gulden). Curr. Opin. Invest. Drugs 3:78-83.
15. Kraft, M., R. Djukanovic, S. Wilson S, et al. 1996. Alveolar tissue inflammation in asthma. Am. J. Respir. Crit. Care Med. 154:1505-1510.
16. Saetta, M., and G. Turato. 2001. Airway pathology in asthma. Eur. Respir. J. 18:18s-23s.
17. Christodoulopoulos, P., D.Y.M. Leung, M. Elliott, et al. 2000. Increased number of glucocorticoid receptor-β-expressing cells in the airways in fatal asthma. J Allergy Clin. Immunol. 106:479-484.
18. Pujols, L., J. Mullol, G. Torrego, et al. 2004. Glucocorticoid receptors in human airways. Allergy 59:1042-1052.
19. Adcock, I.M., T. Gilbey, C.M. Gelder, et al. 1996. Glucocorticoid receptor localization in normal and asthmatic lung. Am. J. Respir. Crit. Care Med. 154:771-782.
20. Leach, C.L., P.J. Davidson, B.E. Hasselquist, et al. 2002. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 122:510-516.
21. Vanden Burgt, J.A., W.W. Busse, R.J. Martin, et al. 2000. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J. Allergy Clin. Immunol. 106:1209-1226.
22. 14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. 43:479-486.
23. Nave, R., R. Fisher, and K. Zech. 2003. In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices. Am. J. Respir. Crit. Care Med. 167:A771(abst).
24. Stoeck, M., R. Riedel, G. Hochhaus, et al. 2004. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J. Pharmacol. Exp. Ther. 309:249-258.
25. Bundschuh, D.S., D. Marx, A. Hatzelmann, et al. 2001. Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide. Presented at the 11th Annual Congress of the European Respiratory Society (ERS), Berlin, Germany.
26. Bundschuh, D.S., R. Riedel, A. Hatzelmann, et al. 2001. Efficacy and safety profile of the novel on-site activated corticosteroid ciclesonide. Am. J. Respir. Crit. Care Med. 163:A588.
27. Belvisi, M.G., D.S. Bundschuh, M. Stoeck, et al. 2001. Preclinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma. Presented at the 11th Annual Congress of the European Respiratory Society (ERS), Berlin, Germany.
28. Drollmann, A., A. Weinbrenner, D. Hüneke, et al. 2001. Repeated inhalation of the new topical steroid ciclesonide does not lead to suppression of endogenous cortisol release in healthy subjects. Presented at the 11th Annual Congress of the European Respiratory Society (ERS), Berlin, Germany.
29. Derom, E., V. Van De Velde, S. Marissens, et al. 2001. Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients. Presented at the 11th Annual Congress of the European Respiratory Society, Berlin, Germany.
30. Drollmann, A., C. Langdon, R. Engelstätter, et al. 2001. Ciclesonide is effective in the treatment of bronchial asthma. Presented at the 11th Annual Congress of the European Respiratory Society, Berlin, Germany.
31. Kanniess, F., K. Richter, S. Böhme, et al. 2001. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm. Pharmacol. Ther. 14:141-147.
32. Postma, D.S., C. Sevette, Y. Martinat, et al. 2001. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. 17:1083-1088.
33. Taylor, D.A., M.W. Jensen, V. Kanabar, et al. 1999. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am. J. Respir. Crit. Care Med. 160:237-243.
34. Taylor, D. A., M.W. Jensen, J.G. Harris, et al. 1997. Airway responsiveness to AMP: a sensitive method to evaluate the dose-response relationship of an inhaled steroid in asthma. Eur. Respir. J. 10:295s(abst).
35. Jensen, M.W., D.A. Taylor, R. Englestatter, et al. 1998. A novel inhaled steroid, ciclesonide, reduces airway responsiveness to AMP in a dose related manner. Presented at the 94th International Conference of the American Thoracic Society (ATS), Chicago.
36. Dahl, R., L.P. Nielsen, M.B. Christensen, et al. 1998. Ciclesonide-an inhaled corticosteroid prodrug-inhibits allergen induced early and late phase reactions. Eur. Respir. J. 12:62s(abst).
37. Schmidt, B.M.W., W. Timmer, A.C. Georgens, et al. 1999. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J. Clin. Pharmacol. 39:1062-1069.
38. Conway, J.H., P. Halson, and E. Moore. 1995. Multimodality imaging: the use of single photon emission computed tomography and magnetic resonance imaging to assess regional intrapulmonary deposition of nebulised aerosols. J. Aerosol Med. 8:293-295.
39. Nave, R., K. Zech, and T.D. Bethke. 2003. Oropharyngeal deposition of inhaled ciclesonide and budesonide in healthy subjects. J. Allergy Clin. Immunol. 111:S220(abst).
40. Tashkin, D.P. 2002. The role of small airway inflammation in asthma. Allergy Asthma Proc. 23:233-242.
41. Warren, S., G. Taylor, J. Smith, et al. 2002. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J. Aerosol Med. 15:15-25.
42. Thorsson, L., S. Edsbäcker, A. Källen, et al. 2001. Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®. Br. J. Clin. Pharmacol. 52:529-538.
43. Johnson, M. 1998. Fluticasone propionate: pharmacokinetic and pharmacodynamic implications of different aerosol delivery systems. Respir. Drug Deliv. 6:61-65.
44. Boobis, A.R. 1998. Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. Respir. Med. 92:2-6.
45. Newman, S.P., G. Woodman, and S.W. Clarke. 1988. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax 43:318-322.